Summary & Overview
HCPCS Level II J0151: Adenosine Injection for Diagnostic Use, 1 mg
HCPCS Level II code J0151 denotes a 1 mg injection of adenosine for diagnostic use and is used in clinical settings performing diagnostic cardiac procedures and pharmacologic stress testing. This code matters nationally because adenosine is a commonly used vasodilator in myocardial perfusion imaging and other diagnostic protocols; accurate coding ensures appropriate billing, clinical documentation, and aggregate tracking of diagnostic pharmaceutical utilization.
Key payers included in the coverage analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the code’s clinical context, typical sites of service, and how the code is positioned within pharmacy and diagnostic service lines. The publication outlines benchmarking considerations, common billing caveats, and relevant policy or coverage themes that affect reimbursement and utilization for injectable diagnostic agents. Where input data is missing, the text notes the absence rather than speculating.
This summary provides clinicians, coders, and billing managers with a clear reference to the code’s purpose, its primary clinical uses, and the payer landscape covered in the analysis.
Billing Code Overview
HCPCS Level II code J0151 represents an injection of adenosine for diagnostic use, 1 mg. The code description specifies that this code is not to be used to report any adenosine phosphate compounds; those should be reported with A9270 instead.
Service type: Diagnostic pharmacologic agent administered by injection.
Typical site of service: Hospital outpatient departments, emergency departments, cardiac catheterization labs, and other clinical settings where diagnostic cardiac procedures or stress testing requiring adenosine are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 55-year-old referred to the cardiology outpatient clinic for evaluation of paroxysmal supraventricular tachycardia (PSVT) characterized by abrupt onset palpitations, lightheadedness, and documented narrow-complex tachycardia on ECG. After history and ECG review, the cardiologist schedules an in-office diagnostic electrophysiology maneuver or an emergency department evaluation where intravenous pharmacologic testing with adenosine is indicated to terminate suspected re-entrant SVT or to unmask underlying atrial activity.
In the clinical workflow, nursing obtains IV access and baseline vitals, and the physician explains rapid bolus administration and transient side effects (flushing, chest pressure, brief asystole). A single diagnostic dose of J0151 (adenosine injection, 1 mg unit billing) is drawn up and administered as a rapid IV push followed by a saline flush. Cardiac rhythm is monitored continuously; if initial dose is ineffective, weight-appropriate escalation per facility protocol is performed using additional vials billed as separate units of J0151. The encounter is documented with indication, dose(s) administered, response (termination of SVT or diagnostic revelation of atrial activity), monitoring, and any adverse events. Typical sites of service include hospital emergency departments, cardiac catheterization or electrophysiology labs, and outpatient cardiology clinics capable of monitored IV administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|